JP2000513806A - 平滑筋細胞における酸化代謝:それに関する方法と物質 - Google Patents
平滑筋細胞における酸化代謝:それに関する方法と物質Info
- Publication number
- JP2000513806A JP2000513806A JP09536885A JP53688597A JP2000513806A JP 2000513806 A JP2000513806 A JP 2000513806A JP 09536885 A JP09536885 A JP 09536885A JP 53688597 A JP53688597 A JP 53688597A JP 2000513806 A JP2000513806 A JP 2000513806A
- Authority
- JP
- Japan
- Prior art keywords
- oxidative metabolism
- smooth muscle
- reagents
- muscle cells
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/904—Oxidation - reduction indicators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.酸化代謝のサポートに適した培地中で、 細胞または組織サンプルを患者由来の標本と共にインキュベートし、該サンプル は平滑筋細胞を含み; 該細胞または組織サンプルの酸化代謝のマーカーを測定し;及び ATPに対する収縮性要求に貢献できない酸化代謝の増大を検出することを含む方 法で、上記酸化代謝の増大は平滑筋細胞における酸化代謝の増大を引き起こしう る試薬または試薬の組み合わせの患者における存在の示唆である方法。 2.ATPに対する収縮性要求に貢献できない平滑筋細胞における酸化代謝の増大に よって特徴づけられる異常な代謝状態を持つ患者の診断、または患者がそれを将 来それを持つであろうことを予想するための請求項1に記載の方法。 3.上記サンプルが血管平滑筋細胞を含み、上記異常な代謝状態が慢性血管痙攣 /血管収縮と関連する請求項2記載の方法。 4.上記試薬または試薬の組み合わせの存在が、患者が血管基底の慢性血管痙攣 /血管収縮を持つ、または将来持つであろうことを指摘する請求項1から3のい ずれか一項記載の方法。 5.該平滑筋細胞が血管基底の血管痙攣/血管収縮の存在を疑うまたは予想する ことに関与するものの代表物である請求項1から4のいずれか一項記載の方法。 6.前子癇、アルツハイマー病または慢性大脳血管痙攣から選択される医療的病 気の診断、予後、予想及び/または定量に関する使用のための請求項1から5の いずれか一項記載の方法。 7.医療的病気が前子癇であり、血管平滑筋細胞が子宮または胎盤血管基底から 、 あるいはへその緒動脈から由来する請求項6記載の方法。 8.医療的病気がアルツハイマー病または慢性大脳血管痙攣であり、血管平滑筋 細胞が大脳血管基底から由来する請求項6記載の方法。 9.血管平滑筋細胞が頸動脈または基底動脈から由来する請求項8記載の方法。 10.頸動脈または基底動脈がブタ起源のものである請求項9記載の方法。 11.ATPに対する収縮性要求に貢献できない平滑筋細胞における酸化代謝の増大 を引き起こすことが可能な試薬または試薬の組み合わせの同定での利用法で、該 方法は酸化代謝のサポートに適した培地中で、 血管平滑筋細胞を含む細胞または組織サンプルを上記試薬または試薬の組み合わ せを含むと考えられる標本と共にインキュベートし; 該細胞または組織サンプルの酸化代謝のマーカーを測定し;及び ATPに対する収縮性要求に貢献できない酸化代謝の増大を検出することを含む方 法で、上記酸化代謝の増大は該標本における上記試薬または試薬の組み合わせの 存在の示唆である方法。 12.該標本が患者由来のサンプルの画分を含む請求項11記載の方法。 13.上記細胞または組織サンプルが血管平滑筋細胞を含む請求項11または請求 項12記載の方法。 14.請求項11から13のいずれか一項記載の方法に引き続き、上記試薬他は試 薬の組み合わせを含む液体標本の同定の方法で、該方法は該試薬または試薬類が 天然で関連している生物学的分子から実質的にフリーであるように、上記試薬ま たは試薬の組み合わせを精製及び分離することを含む方法。 15.請求項11から13のいずれか一項記載の方法に引き続き、上記試薬または 試薬の組み合わせを含む液体標本の同定の方法で、該方法は上記試薬または試薬 の組み合わせを特性指摘することを含む方法。 16.請求項14または請求項15記載の方法に引き続き、その生物学的活性を実 質的に維持する上記試薬または試薬の組み合わせの合成バージョンまたは誘導体 の調製を含む方法。 17.治療上の試薬としての潜在的な効力に対する化合物のスクリーニング法で、 該方法は酸化代謝のサポートに適した培地中で、 平滑筋細胞を含む細胞または組織サンプルを(a)ATPに対する収縮性要求に貢献で きない細胞または組織サンプルの酸化代謝の増大に影響することが知られた標本 、試薬または試薬の組み合わせ;及び(b)試験化合物と共にインキュベートし; 酸化代謝のマーカーを測定し;及び 通常該標本、試薬または試薬の組み合わせによって影響される、ATPに対する収 縮性要求に貢献できない酸化代謝の増大の不存在または減少を検出することを含 む方法で、上記不存在または減少は試験化合物が治療試薬として潜在的な効力を 持つ示唆である方法。 18.細胞または組織サンプルが血管平滑筋細胞を含む請求項17記載の方法。 19.請求項17または請求項18記載の方法に引き続いて、治療上の試薬として の潜在的な効力を持つ試験化合物の同定法で、該方法は試験化合物の生物学的活 性を実質的に維持する試験化合物の合成バージョンまたは誘導体の調製を含む方 法。 20.請求項17または請求項18記載の方法に引き続いて、治療上の試薬として の潜在的な効力を持つ試験化合物の同定法、または請求項19記載の方法に引き 続いて、試験化合物の合成バージョンまたは誘導体の調整法で、該方法は治療上 の有効量で試験化合物またはその誘導体を持つ医薬品の調製を含む方法。 21.患者に投与される治療の効果をモニターする方法で、該方法は請求項1から 10項のいずれか一項記載の方法を実施し、ATPに対する収縮性の要求に対して 貢献できない酸化代謝の増大の改変を検出するために、一つ以上の適切に選択さ れた時間間隔で上記方法を繰り返すことを含み、そしてその場合該増大の減少が 該治療は治療上有利であることを示唆する方法。 22.該標本がCSF;血液、血清及び血漿より選択される請求項1から21のいず れか一項記載の方法。 23.酸化代謝のマーカーが該細胞または組織サンプルにおける酸素消費割合、AT Pアーゼ活性、キナーゼ活性、ミオシンのリン酸化状態またはADP濃度より選択さ れる請求項1から22のいずれか一項記載の方法。 24.上記培地が11mMのグルコース及び/または5mMのピルビン酸塩を含むKrebs、 または11mMのグルコース及び/または5mMのピルビン酸塩と共に0.5mM KH2PO4を 含むKrebs-Hensleitバッファーを含む請求項1から23のいずれか一項記載の方 法。 25.上記培地が生存可能な微生物からフリーである請求項1から24のいずれか 一項記載の方法。 26.該インキュベーションが95%O2及び5%CO2を用いて空気を与えられる請求項1 から25のいずれか一項記載の方法。 27.該インキュベーションが細胞または組織サンプルの酸化代謝をサポートする pHで実施される請求項1から26のいずれか一項記載の方法。 28.該インキュベーションが実質的に7.4で実施される請求項1から27のいず れ か一項記載の方法。 29.クモ膜下出血の患者及び慢性血管痙攣に陥る危険のある患者を治療する方法 で、該方法は血管平滑筋細胞をそのラッチされたまたは収縮状態にする化合物、 または請求項20記載の方法で生産された医薬品の治療上の有効量を患者に投与 することを含む方法。 30.ヒスタミン及び/またはドブタミンの治療上の有効量を投与することを含む 請求項29記載の方法。 31.クモ膜下出血の患者及び慢性大脳血管痙攣に陥る危険のある患者、または慢 性大脳血管痙攣の患者の治療に対する医薬の調製における、請求項20記載の方 法で生産される医薬品、ドブタミン及びヒスタミンの一つ以上の使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9608046.0A GB9608046D0 (en) | 1996-04-18 | 1996-04-18 | Smooth muscle constrictions and spasms: methods and materials relating thereto |
GB9608046.0 | 1996-04-18 | ||
GBGB9610915.2A GB9610915D0 (en) | 1996-05-24 | 1996-05-24 | Smoooth muscle constrictions and spasms methods and materials relating thereto |
GB9610915.2 | 1996-05-24 | ||
GB9702509.2 | 1997-02-07 | ||
GBGB9702509.2A GB9702509D0 (en) | 1997-02-07 | 1997-02-07 | Smooth muscle constrictions and spasms:methods and materials relating thereto |
PCT/GB1997/001086 WO1997039353A1 (en) | 1996-04-18 | 1997-04-18 | Oxidative metabolism in smooth muscle cells: methods and materials relating thereto |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000513806A true JP2000513806A (ja) | 2000-10-17 |
JP3759620B2 JP3759620B2 (ja) | 2006-03-29 |
Family
ID=27268251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53688597A Expired - Fee Related JP3759620B2 (ja) | 1996-04-18 | 1997-04-18 | 平滑筋細胞における酸化代謝:それに関する方法と物質 |
Country Status (8)
Country | Link |
---|---|
US (2) | US6080385A (ja) |
EP (1) | EP0898707B1 (ja) |
JP (1) | JP3759620B2 (ja) |
AT (1) | ATE344454T1 (ja) |
AU (1) | AU2394597A (ja) |
DE (1) | DE69736893T2 (ja) |
ES (1) | ES2276423T3 (ja) |
WO (1) | WO1997039353A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0003225D0 (en) * | 2000-02-11 | 2000-04-05 | Medical Res Council | Models, methods and materials relating to clinical conditions associated with reactive oxygen species |
GB0004549D0 (en) | 2000-02-25 | 2000-04-19 | Isis Innovation | Degradation fragments |
EP1330267A4 (en) * | 2000-07-07 | 2005-10-12 | Panacea Pharmaceuticals Inc | OLFACTORY NEURON CULTURES, METHODS OF MAKING AND USING |
US20040157280A1 (en) * | 2001-09-17 | 2004-08-12 | Paul Wentworth | Antibody mediated ozone generation |
US20040116350A1 (en) * | 2001-09-17 | 2004-06-17 | Paul Wentworth Jr | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
US20050129680A1 (en) * | 2001-09-17 | 2005-06-16 | Paul Wentworth | Antimicrobial activity of antibodies |
US20060292076A1 (en) * | 2002-11-14 | 2006-12-28 | Paul Wentworth | Antimicrobial mediated ozone generation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4445500A (en) * | 1982-03-03 | 1984-05-01 | Thomas Jefferson University | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
-
1997
- 1997-04-18 AT AT97919499T patent/ATE344454T1/de not_active IP Right Cessation
- 1997-04-18 WO PCT/GB1997/001086 patent/WO1997039353A1/en active IP Right Grant
- 1997-04-18 AU AU23945/97A patent/AU2394597A/en not_active Abandoned
- 1997-04-18 ES ES97919499T patent/ES2276423T3/es not_active Expired - Lifetime
- 1997-04-18 JP JP53688597A patent/JP3759620B2/ja not_active Expired - Fee Related
- 1997-04-18 EP EP97919499A patent/EP0898707B1/en not_active Expired - Lifetime
- 1997-04-18 DE DE69736893T patent/DE69736893T2/de not_active Expired - Lifetime
-
1998
- 1998-10-19 US US09/174,581 patent/US6080385A/en not_active Expired - Fee Related
-
2000
- 2000-05-16 US US09/571,932 patent/US6284542B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0898707B1 (en) | 2006-11-02 |
ATE344454T1 (de) | 2006-11-15 |
AU2394597A (en) | 1997-11-07 |
US6284542B1 (en) | 2001-09-04 |
DE69736893D1 (de) | 2006-12-14 |
US6080385A (en) | 2000-06-27 |
WO1997039353A1 (en) | 1997-10-23 |
EP0898707A1 (en) | 1999-03-03 |
ES2276423T3 (es) | 2007-06-16 |
DE69736893T2 (de) | 2007-09-06 |
JP3759620B2 (ja) | 2006-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Distelhorst et al. | Bcl-2 interaction with the inositol 1, 4, 5-trisphosphate receptor: role in Ca2+ signaling and disease | |
Harrod et al. | Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review | |
Prasad et al. | TAM receptor function in the retinal pigment epithelium | |
CN110208533B (zh) | Pkal-介导的病症的评估、测定和治疗 | |
JPH05506990A (ja) | プロテアーゼ ネキシン―2の精製、検出、及び使用方法 | |
Messing et al. | Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors | |
JP2002504999A (ja) | 心疾患の早期発見のための方法 | |
JP2000507828A (ja) | アルツハイマー病の診断および治療法 | |
EP0460078A1 (en) | Pharmaceutically active agents that impede amyloid formation in vivo | |
Yu et al. | Cholecystokinin-coupled intracellular signaling in human gallbladder muscle | |
US5536639A (en) | Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products | |
JP3759620B2 (ja) | 平滑筋細胞における酸化代謝:それに関する方法と物質 | |
CN105368975B (zh) | 颅内动脉瘤标志物odam及其应用 | |
Hébert et al. | Distant space processing is controlled by tPA-dependent NMDA receptor signaling in the entorhinal cortex | |
Koeppen | Neuropathology of the inherited ataxias | |
Alexander et al. | Delayed CSF lavage for arteriographic and morphological vasospasm after experimental SAH | |
KR20160086775A (ko) | Pin1 저해제를 유효성분으로 포함하는 뇌졸중 예방 또는 치료용 약학적 조성물 | |
JP2010540892A (ja) | 抗炎症活性を有する化合物をスクリーニングする方法 | |
Fernández et al. | Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients | |
JP4503287B2 (ja) | 星状細胞及び星状細胞性腫瘍細胞の増殖を阻害する方法と、ニューロンの生存を高める方法、並びにその使用 | |
Meckelein et al. | Identification of a novel serine protease-like molecule in human brain | |
Zhang et al. | Separate and synergistic effect of progesterone and estradiol on induction of annexin 2 and its interaction protein p11 in pregnant sheep myometrium | |
JP3797890B2 (ja) | エラスチン分解物の測定方法及び測定キットならびに大動脈解離症の検出方法及び検出キット | |
Dias | Impact of Nlrp3 inflammasome inhibition on a model of Aβ-induced toxicity | |
Ramasundari Ilambirai | Utility of platelet indices as indicators of vascular complications in diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050926 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060104 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100113 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110113 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |